Cargando…

Multidimensional daily diary of fatigue–fibromyalgia–17 items (MDF-fibro-17). part 1: development and content validity

BACKGROUND: Fibromyalgia (FM), a disorder characterized by chronic widespread pain and tenderness, affects greater than five million individuals in the United States alone. Patients experience multiple symptoms in addition to pain, and among them, fatigue is one of the most bothersome and disabling....

Descripción completa

Detalles Bibliográficos
Autores principales: Morris, S., Li, Y., Smith, J.A.M., Dube’, S., Burbridge, C., Symonds, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434627/
https://www.ncbi.nlm.nih.gov/pubmed/28511678
http://dx.doi.org/10.1186/s12891-017-1544-y
_version_ 1783237086754635776
author Morris, S.
Li, Y.
Smith, J.A.M.
Dube’, S.
Burbridge, C.
Symonds, T.
author_facet Morris, S.
Li, Y.
Smith, J.A.M.
Dube’, S.
Burbridge, C.
Symonds, T.
author_sort Morris, S.
collection PubMed
description BACKGROUND: Fibromyalgia (FM), a disorder characterized by chronic widespread pain and tenderness, affects greater than five million individuals in the United States alone. Patients experience multiple symptoms in addition to pain, and among them, fatigue is one of the most bothersome and disabling. There is a growing body of literature suggesting that fatigue is a multidimensional concept. Currently, to our knowledge, no multidimensional Patient Reported Outcome (PRO) measure of FM-related fatigue meets Food and Drug Administration (FDA) requirements to support a product label claim. Therefore, the objective of this research was to evaluate qualitative and quantitative data previously gathered to inform the development of a comprehensive, multidimensional, PRO measure to assess FM-related fatigue in FM clinical trials. METHODS: Existing qualitative and quantitative data from three previously conducted studies in patients with FM were reviewed to inform the initial development of a multidimensional PRO measure of FM-related fatigue: 1) a concept elicitation study involving in-depth, open-ended interviews with patients with FM in the United States (US) (N = 20), Germany (N = 10), and France (N = 10); 2) a cognitive debriefing and pilot study of a preliminary pool of 23 items (N = 20 US patients with FM); and 3) a methodology study that explored initial psychometrics of the item pool (N = 145 US patients with FM). RESULTS: Five domains were identified that intend to capture the broad experience of FM-related fatigue reported in the qualitative research: the Global Fatigue Experience, Cognitive Fatigue, Physical Fatigue, Motivation, and Impact on Function. Seventeen of the original pool of 23 items were selected to best capture these five dimensions. These 17 items formed the basis of a newly developed multidimensional PRO measure to assess FM-related fatigue in clinical trials: the Multidimensional Daily Diary of Fatigue-Fibromyalgia-17 (MDF-Fibro-17). CONCLUSION: Qualitative analysis, and preliminary quantitative item level data, confirmed that FM-related fatigue is multidimensional and provided strong support for the content validity of the MDF-Fibro-17. The next stage was to quantitatively evaluate the measure to confirm the factor structure, psychometric properties, sensitivity to change, and meaningful change. This has been conducted and is being reported separately.
format Online
Article
Text
id pubmed-5434627
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54346272017-05-18 Multidimensional daily diary of fatigue–fibromyalgia–17 items (MDF-fibro-17). part 1: development and content validity Morris, S. Li, Y. Smith, J.A.M. Dube’, S. Burbridge, C. Symonds, T. BMC Musculoskelet Disord Research Article BACKGROUND: Fibromyalgia (FM), a disorder characterized by chronic widespread pain and tenderness, affects greater than five million individuals in the United States alone. Patients experience multiple symptoms in addition to pain, and among them, fatigue is one of the most bothersome and disabling. There is a growing body of literature suggesting that fatigue is a multidimensional concept. Currently, to our knowledge, no multidimensional Patient Reported Outcome (PRO) measure of FM-related fatigue meets Food and Drug Administration (FDA) requirements to support a product label claim. Therefore, the objective of this research was to evaluate qualitative and quantitative data previously gathered to inform the development of a comprehensive, multidimensional, PRO measure to assess FM-related fatigue in FM clinical trials. METHODS: Existing qualitative and quantitative data from three previously conducted studies in patients with FM were reviewed to inform the initial development of a multidimensional PRO measure of FM-related fatigue: 1) a concept elicitation study involving in-depth, open-ended interviews with patients with FM in the United States (US) (N = 20), Germany (N = 10), and France (N = 10); 2) a cognitive debriefing and pilot study of a preliminary pool of 23 items (N = 20 US patients with FM); and 3) a methodology study that explored initial psychometrics of the item pool (N = 145 US patients with FM). RESULTS: Five domains were identified that intend to capture the broad experience of FM-related fatigue reported in the qualitative research: the Global Fatigue Experience, Cognitive Fatigue, Physical Fatigue, Motivation, and Impact on Function. Seventeen of the original pool of 23 items were selected to best capture these five dimensions. These 17 items formed the basis of a newly developed multidimensional PRO measure to assess FM-related fatigue in clinical trials: the Multidimensional Daily Diary of Fatigue-Fibromyalgia-17 (MDF-Fibro-17). CONCLUSION: Qualitative analysis, and preliminary quantitative item level data, confirmed that FM-related fatigue is multidimensional and provided strong support for the content validity of the MDF-Fibro-17. The next stage was to quantitatively evaluate the measure to confirm the factor structure, psychometric properties, sensitivity to change, and meaningful change. This has been conducted and is being reported separately. BioMed Central 2017-05-16 /pmc/articles/PMC5434627/ /pubmed/28511678 http://dx.doi.org/10.1186/s12891-017-1544-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Morris, S.
Li, Y.
Smith, J.A.M.
Dube’, S.
Burbridge, C.
Symonds, T.
Multidimensional daily diary of fatigue–fibromyalgia–17 items (MDF-fibro-17). part 1: development and content validity
title Multidimensional daily diary of fatigue–fibromyalgia–17 items (MDF-fibro-17). part 1: development and content validity
title_full Multidimensional daily diary of fatigue–fibromyalgia–17 items (MDF-fibro-17). part 1: development and content validity
title_fullStr Multidimensional daily diary of fatigue–fibromyalgia–17 items (MDF-fibro-17). part 1: development and content validity
title_full_unstemmed Multidimensional daily diary of fatigue–fibromyalgia–17 items (MDF-fibro-17). part 1: development and content validity
title_short Multidimensional daily diary of fatigue–fibromyalgia–17 items (MDF-fibro-17). part 1: development and content validity
title_sort multidimensional daily diary of fatigue–fibromyalgia–17 items (mdf-fibro-17). part 1: development and content validity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434627/
https://www.ncbi.nlm.nih.gov/pubmed/28511678
http://dx.doi.org/10.1186/s12891-017-1544-y
work_keys_str_mv AT morriss multidimensionaldailydiaryoffatiguefibromyalgia17itemsmdffibro17part1developmentandcontentvalidity
AT liy multidimensionaldailydiaryoffatiguefibromyalgia17itemsmdffibro17part1developmentandcontentvalidity
AT smithjam multidimensionaldailydiaryoffatiguefibromyalgia17itemsmdffibro17part1developmentandcontentvalidity
AT dubes multidimensionaldailydiaryoffatiguefibromyalgia17itemsmdffibro17part1developmentandcontentvalidity
AT burbridgec multidimensionaldailydiaryoffatiguefibromyalgia17itemsmdffibro17part1developmentandcontentvalidity
AT symondst multidimensionaldailydiaryoffatiguefibromyalgia17itemsmdffibro17part1developmentandcontentvalidity